New Antibiotic Ceftobiprole Could Help Fight Resistant Staph Infections
Medically reviewed by Drugs.com.
By Cara Murez HealthDay Reporter
THURSDAY, Sept. 28, 2023 -- New research shows that an antibiotic effective for bacterial pneumonia also appears to fight treatment-resistant staph infections.
The drug is ceftobiprole. It appeared successful in fighting methicillin-resistant staph infections, sometimes called MRSA. It showed similar benefit when tested against the antibiotic daptomycin to treat complicated Staphylococcus aureus infections.
This means it could offer another option against this common and often deadly bacterial infection, according to the research led by Duke Health in Durham, N.C.
“This is an area of true need,” Dr. Thomas Holland, associate professor at Duke University School of Medicine and chair of the study's data review committee, said in a Duke Health news release. “There has not been a new antibiotic approved for the treatment of S. aureus bacteremia for over 15 years.”
The researchers studied the antibiotics in 390 patients in 17 countries who had complicated staph infections between 2018 and 2022. Roughly half were randomly assigned to receive infusions of ceftobiprole. The other half were treated intravenously with daptomycin.
The investigators assessed safety and overall treatment success, measured as survival, clearance of bacteria from the bloodstream, symptom improvement and no new bacterial complications 70 days after treatment.
Both antibiotics performed similarly.
In the ceftobiprole group, 69.8% of patients experienced overall success. That was compared to 68.7% in the daptomycin group. Gastrointestinal issues were the most common side effect for both drugs.
“Despite a lot of work in medical science, complicated staph infections still have a 25% [death] rate at 90 days,” said study co-author Dr. Vance Fowler, a professor of medicine and molecular genetics and microbiology at Duke. “We need more options for treating these infections.”
The study was sponsored by Basilea Pharmaceutica International Ltd., which markets ceftobiprole. Ceftobiprole is not approved in the US.
The findings were published online Sept. 27 in the New England Journal of Medicine.
Sources
- Duke Health, news release, Sept. 27, 2023
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Utah Kids Got E. Coli From Playing Around Lawn Sprinklers
FRIDAY, May 10, 2024 -- Happily jumping around lawn sprinklers or playing with garden hoses on a hot summer day: An idyllic childhood scene. Not so for a bunch of kids in Utah...
Americans Got Drug-Resistant Infections After Stem Cell Treatments in Mexico
THURSDAY, May 9, 2024 -- Antibiotic-resistant meningitis or severe, long-lasting joint infections: That's what three U.S. "medical tourists" brought home after seeking out...
Avoid Some 'Project Watson' Dog Eye Wipes Due to Infection Danger
MONDAY, May 6, 2024 -- Pets and pet owners who come into contact with Bausch & Lomb's "Project Watson" dog eye wipes could be at risk for infection if the products come from...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
